This Dividend Feels Illegal 🚫

Your current options for finding stock trades:

Option 1: Spend 4 hours daily reading everything online
Option 2: Pay $500/month for paywalled newsletters and pray
Option 3: Get yesterday's news from mainstream financial media

All three keep you broke.

Here's where the actual edge lives:

The problem? You'd need to be terminally online to track it all.

Stocks & Income monitors every corner where real money gets made. We send you only the actionable opportunities. No fluff, no yesterday's headlines.

Five minutes daily. Walk away with stock insights you can actually act on every time.

Subscribe to Stocks & Income

_{Stocks & Income is for informational purposes only and is not intended to be used as investment advice. Do your own research.}

If Warren Buffett and The Rock had a baby, it would probably look a lot like $ABBV ( ▼ 1.15% ). Strong, consistent, dependable. And always cutting you a check every quarter.

This isn’t your grandpa’s sleepy dividend payer. AbbVie is a Dividend King with over 50 years of hikes under its belt (counting its Abbott Labs days). But unlike most Kings that toss out token raises, AbbVie still hands out meaty pay bumps.

And right now, it’s flashing a rare combo that dividend growth investors drool over:

Yep. AbbVie’s basically the golden retriever of pharma stocks. Loyal, hardworking, and pays you back with tail wags dividends.

AbbVie split from Abbott Labs in 2013. Since then, it’s pumped its dividend up by 310%. That’s a monster raise in just over a decade.

Go back even further and you get legendary stories like Grace Groner — Abbott secretary in the 1930s, bought 3 shares for $180, never sold. By the time she passed in 2010? That tiny investment had ballooned into $7.2 million.

That’s the power of sticking with a compounding machine. And AbbVie’s track record shows it’s still in the game.

At first glance, the payout ratio looks terrifying: it shot from 80% in late 2022 to 308% now. But that’s just accounting noise from one-off impairments.

The real picture? In Q2, AbbVie delivered adjusted EPS of $2.97. The dividend that quarter was $1.64. That’s a comfortable 55% payout ratio.

And the growth’s been steady:

Not Microsoft-level 10%+ hikes, but here’s the trade off: Microsoft trades at sky-high multiples. AbbVie gives you nearly the same dividend growth plus a chunky yield today.

Humira, AbbVie’s once-golden goose, lost U.S. patent protection in 2023. It’s still kicking with $1.18B in sales, but the real stars now are Skyrizi and Rinvoq:

Add in:

Still, AbbVie grew revenues +6.5% YoY and EPS +12.1% YoY in Q2. Management even bumped full-year EPS guidance up to $11.88–$12.08 (midpoint: $11.98).

Pipeline looks solid too, with new trials showing promise. And you know what that means right? More ammo for dividends.

Circle your calendar. Every late October, AbbVie announces its annual dividend raise. Here’s the recent pattern:

This year? With stronger earnings and a 55% payout ratio, AbbVie’s got wiggle room. Expect something like a $0.10 bump, bringing the quarterly dividend to $1.74. That’s a 6.1% hike. Slightly juicier than last year, still well within safe territory.

AbbVie isn’t risk-free. Here’s what could bite:

How does AbbVie stack up against peers $AMGN ( ▼ 3.02% ) and $GILD ( ▼ 1.14% )?

AbbVie’s the priciest on P/S and P/E, but still trading under 20x earnings. Compare that to consumer staples at 20–25x with worse growth.

Wall Street expects AbbVie to pump out 15% EPS growth annually for the next 5 years. Toss in the 3% dividend yield, and you’re looking at ~18% total annual returns. That’s been reality the last 5 years, and AbbVie could easily run it back.

AbbVie isn’t just a Dividend King. It’s a Dividend King that still acts like it’s climbing the throne. Solid growth, conservative payout ratio, and a dividend hike tradition that feels as reliable as your morning coffee.

Even after a 153% stock price run in the last 5 years (20% CAGR before dividends), AbbVie still looks like a Strong Buy for dividend growth investors.